Health Catalyst Reports Massive Q4 Net Loss, $110M Impairment, and Withdraws Full-Year Guidance
Summary
Health Catalyst reported a substantial Q4 net loss of $91 million, including an $81.45 million goodwill impairment, and withdrew its full-year 2026 guidance, signaling significant operational challenges.
Key Events
-
Massive Net Loss Reported
Q4 2025 net loss widened to $(91.025) million, a 340% increase year-over-year, with full-year net loss at $(177.974) million.
-
Significant Asset Impairment Charge
The company recognized $81.454 million in goodwill and intangible asset impairment in Q4 2025, contributing to a total of $110.223 million for the full year.
-
Full-Year Guidance Withdrawn
Health Catalyst did not provide full-year 2026 guidance due to an ongoing strategic and operational review related to a CEO transition, creating uncertainty.
-
Declining Revenue and Retention Rate
Q4 2025 total revenue decreased by 6% year-over-year, and the dollar-based retention rate for 2025 fell to 93% from 102% in 2024.
Analysis
Health Catalyst reported a significantly wider net loss for Q4 and the full year 2025, primarily driven by a substantial $110.2 million goodwill and intangible asset impairment charge. This impairment, representing a large portion of the company's market capitalization, signals a significant revaluation of asset values and potentially underperforming business units. The company also experienced a decline in Q4 revenue and a drop in its dollar-based retention rate. The decision to withhold full-year 2026 guidance due to an ongoing strategic review and CEO transition introduces considerable uncertainty. While Adjusted EBITDA improved and the company repurchased $5 million in stock, these positives are overshadowed by the severe GAAP losses and asset write-downs, indicating significant operational challenges and a need for strategic re-evaluation, especially as the stock trades near 52-week lows.
At the time of this filing, HCAT was trading at $1.60 on NASDAQ in the Technology sector, with a market capitalization of approximately $126.6M. The 52-week trading range was $1.56 to $5.06. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.